144 related articles for article (PubMed ID: 28043824)
1. ESR1 and its antagonist fulvestrant in pituitary adenomas.
Gao H; Xue Y; Cao L; Liu Q; Liu C; Shan X; Wang H; Gu Y; Zhang Y
Mol Cell Endocrinol; 2017 Mar; 443():32-41. PubMed ID: 28043824
[TBL] [Abstract][Full Text] [Related]
2. Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study.
Hannen R; Steffani M; Voellger B; Carl B; Wang J; Bartsch JW; Nimsky C
J Steroid Biochem Mol Biol; 2019 Mar; 187():88-96. PubMed ID: 30439415
[TBL] [Abstract][Full Text] [Related]
3. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models.
Cao L; Gao H; Gui S; Bai G; Lu R; Wang F; Zhang Y
J Neurooncol; 2014 Feb; 116(3):523-31. PubMed ID: 24407733
[TBL] [Abstract][Full Text] [Related]
4. TNF-α can promote membrane invasion by activating the MAPK/MMP9 signaling pathway through autocrine in bone-invasive pituitary adenoma.
Wu X; Gong L; Li B; Bai J; Li C; Zhang Y; Zhu H
CNS Neurosci Ther; 2024 May; 30(5):e14749. PubMed ID: 38739004
[TBL] [Abstract][Full Text] [Related]
5. Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.
Selek A; Halbutoğulları ZSU; Aydemir Çİ; Cetinarslan B; Canturk Z; Tarkun I; Erman G; Subaşı C; Erdal K
Mol Neurobiol; 2023 May; 60(5):2442-2454. PubMed ID: 36662360
[TBL] [Abstract][Full Text] [Related]
6. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
7. Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
Pituitary; 2014 Jun; 17(3):203-9. PubMed ID: 23649927
[TBL] [Abstract][Full Text] [Related]
8. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
10. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Cao L; Gao H; Li P; Gui S; Zhang Y
Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
[TBL] [Abstract][Full Text] [Related]
11. Accurate assessment of estrogen receptor profiles in non-functioning pituitary adenomas using RT-digital PCR and immunohistochemistry.
Hattori Y; Ishii H; Tahara S; Morita A; Ozawa H
Life Sci; 2020 Nov; 260():118416. PubMed ID: 32926922
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway.
Wang C; Bai M; Wang X; Tan C; Zhang D; Chang L; Li G; Xie L; Su J; Wen Y
Mol Med Rep; 2018 Oct; 18(4):4037-4041. PubMed ID: 30106152
[TBL] [Abstract][Full Text] [Related]
13. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
15. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
16. Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway.
Wang J; Zhang Z; Li R; Sun W; Chen J; Zhang H; Shu K; Lei T
Life Sci; 2018 Feb; 194():150-156. PubMed ID: 29288766
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
Hubina E; Nanzer AM; Hanson MR; Ciccarelli E; Losa M; Gaia D; Papotti M; Terreni MR; Khalaf S; Jordan S; Czirják S; Hanzély Z; Nagy GM; Góth MI; Grossman AB; Korbonits M
Eur J Endocrinol; 2006 Aug; 155(2):371-9. PubMed ID: 16868153
[TBL] [Abstract][Full Text] [Related]
18. Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.
Rui QH; Ma JB; Liao YF; Dai JH; Cai ZY
Braz J Med Biol Res; 2019; 52(4):e7728. PubMed ID: 30994730
[TBL] [Abstract][Full Text] [Related]
19. Ubenimex induces apoptotic and autophagic cell death in rat GH3 and MMQ cells through the ROS/ERK pathway.
Wang Y; Pang B; Zhang R; Fu Y; Pang Q
Drug Des Devel Ther; 2019; 13():3217-3228. PubMed ID: 31571825
[TBL] [Abstract][Full Text] [Related]
20. Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors.
Caronti B; Palladini G; Bevilacqua MG; Petrangeli E; Fraioli B; Cantore G; Tamburrano G; Carapella CM; Jaffrain-Rea ML
Tumour Biol; 1993; 14(1):59-68. PubMed ID: 8493452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
